Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsTargeting Angiogenesis in Biliary Tract Cancers: An Open OptionEfficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis.Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.Therapeutic options for intrahepatic cholangiocarcinomaThe potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials.Pediatric Kawasaki Disease and Adult Human Immunodeficiency Virus Kawasaki-Like Syndrome Are Likely the Same Malady.The Wnt/β-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment.From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic CancersNew Horizons for Precision Medicine in Biliary Tract Cancers.Emerging molecular targets and therapy for cholangiocarcinoma.Immunotherapeutic Approaches to Biliary Cancer.Novel investigational therapies for treating biliary tract carcinoma.Current Progress in Immunotherapy for the Treatment of Biliary Cancers.HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?Intrahepatic cholangiocarcinoma: current management and emerging therapies.Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.Current biologics for treatment of biliary tract cancers.Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients.Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma.Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma.New molecular and immunotherapeutic approaches in biliary cancer.Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico.Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case reportPlasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer
P2860
Q26751224-9231D503-B635-44D2-B59D-9650C8A0E5BFQ30398807-1492C4BE-ADFA-4A4B-934C-1CBBB49648C6Q33436600-A2AE72D3-5085-4C59-8071-17A1C6DC70E3Q33440859-326E22B9-14C3-4963-8596-8DB1D7DE9E74Q33621529-57CF8FEF-59EE-4144-8B3B-C2060B6BF1E7Q33656860-39680C36-3262-4A6C-8D4B-2B3CB69A0409Q33688577-315E16A2-D4A7-406A-8A82-DF431B8C2D74Q35934963-D63B0A1B-A083-40EB-B125-576E6BE68305Q36107068-6F3A018B-0666-4105-80CE-C2E7BF901587Q37305538-ABB341E0-75AC-4E1C-BFD4-DCA27011F31AQ37393508-48220C95-12AB-4A5A-A8D8-47D316ACDA59Q37631655-3313D45D-9F90-4B8A-A75E-A306AC8F1409Q38619219-772015C2-812D-4724-B5E3-22E9D036D8FEQ38642455-0F2ED173-EC94-40D6-A481-791A8F9A0812Q38703148-618B113F-7551-4C7B-BCCA-C2C4FB7FF6E1Q38799963-EC8B9A9C-6213-4186-8FBA-7208E55148CEQ38830071-481F1A4E-A873-493D-BD19-A45EB966184AQ39040859-46CAD1AC-6D51-4DD4-ACBD-E8981CF35B3DQ39186928-FDB4302C-016B-4B58-A4E6-A37016A1604FQ39289707-D3241881-5273-4FFF-8A24-A19603DC0FEFQ39385781-280A737B-9F47-4573-ADBB-05BC11ED09B9Q39453572-D35C4194-FAE8-422A-B577-F4317D5CA219Q39521003-77A7ED9B-1B1B-48D8-B9BC-5464B26C8720Q40824695-AA1F2362-ECD3-46FF-841A-01D4E4FC86D2Q47139810-42DBC4B4-EB28-4E13-BD09-5FE1FB2FC30EQ47429093-FBEBA659-3D77-4E1A-9696-B71285347B62Q48203761-C01212C0-243E-401E-B998-2D3F46585F6EQ48214785-4C8B538A-D71F-4839-A4E4-637FBA661CD0Q49627919-A025E30C-2B7B-4C0D-B49B-F9A8D0023CD2Q50526996-CA99E8FB-63B8-422A-9683-A201FC09026FQ54476966-CE954C6E-4D79-4664-B881-49972289D357Q55481891-EE8F6B25-F0CE-4D68-944C-8684416BD54CQ57073983-0AACCAC7-F41E-4BB1-BB3B-5A76D66DD2B8Q58599860-5321ACA2-A245-4574-A14B-8E1240586201
P2860
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@ast
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@en
type
label
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@ast
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@en
prefLabel
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@ast
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@en
P2093
P2860
P50
P921
P1433
P1476
Cediranib or placebo in combin ...... ): a randomised phase 2 trial.
@en
P2093
Alison C Backen
Andre Lopes
Anthony Maraveyas
Charlotte Rees
D Alan Anthoney
Daniel H Palmer
Harpreet Wasan
John A Bridgewater
Justin S Waters
Karen Morris
P2860
P304
P356
10.1016/S1470-2045(15)00139-4
P577
2015-07-12T00:00:00Z